145 related articles for article (PubMed ID: 37864443)
41. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
42. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
43. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.
Peková S; Marková J; Pajer P; Dvorák M; Cetkovský P; Schwarz J
Mol Diagn; 2005; 9(1):23-34. PubMed ID: 16035732
[TBL] [Abstract][Full Text] [Related]
44. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
45. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
Thompson PA; Wierda WG
Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
[TBL] [Abstract][Full Text] [Related]
46. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
Front Oncol; 2019; 9():689. PubMed ID: 31555576
[TBL] [Abstract][Full Text] [Related]
47. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
[TBL] [Abstract][Full Text] [Related]
48. MRD in CLL.
Hillmen P
Clin Adv Hematol Oncol; 2006 May; 4(5):6-7; discussion 10; suppl 12. PubMed ID: 16830420
[No Abstract] [Full Text] [Related]
49. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
[TBL] [Abstract][Full Text] [Related]
50. Minimal residual disease assessment in chronic lymphocytic leukaemia.
Sayala HA; Rawstron AC; Hillmen P
Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
[TBL] [Abstract][Full Text] [Related]
51. Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.
Böttcher S
Methods Mol Biol; 2019; 1956():157-197. PubMed ID: 30779035
[TBL] [Abstract][Full Text] [Related]
52. A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?
Ghia P
Hematology Am Soc Hematol Educ Program; 2012; 2012():97-104. PubMed ID: 23233566
[TBL] [Abstract][Full Text] [Related]
53. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
54. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
Theunissen P; Mejstrikova E; Sedek L; van der Sluijs-Gelling AJ; Gaipa G; Bartels M; Sobral da Costa E; Kotrová M; Novakova M; Sonneveld E; Buracchi C; Bonaccorso P; Oliveira E; Te Marvelde JG; Szczepanski T; Lhermitte L; Hrusak O; Lecrevisse Q; Grigore GE; Froňková E; Trka J; Brüggemann M; Orfao A; van Dongen JJ; van der Velden VH;
Blood; 2017 Jan; 129(3):347-357. PubMed ID: 27903527
[TBL] [Abstract][Full Text] [Related]
55. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
[TBL] [Abstract][Full Text] [Related]
56. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia.
Maloum K; Charlotte F; Divine M; Cazin B; Lesty C; Merle-Béral H;
Haematologica; 2006 Jun; 91(6):860-1. PubMed ID: 16769593
[TBL] [Abstract][Full Text] [Related]
57. Is MRD eradication a desirable goal in CLL?
Moreno C; Ritgen M; Rawstron A
Best Pract Res Clin Haematol; 2010 Mar; 23(1):97-107. PubMed ID: 20620974
[TBL] [Abstract][Full Text] [Related]
58. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
Algrin C; Golmard JL; Michallet M; Reman O; Huynh A; Perrot A; Sirvent A; Plesa A; Salaun V; Béné MC; Bories D; Tournilhac O; Merle-Béral H; Leblond V; Le Garff-Tavernier M; Dhedin N
Eur J Haematol; 2017 Apr; 98(4):363-370. PubMed ID: 27943415
[TBL] [Abstract][Full Text] [Related]
59. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
Logan AC; Zhang B; Narasimhan B; Carlton V; Zheng J; Moorhead M; Krampf MR; Jones CD; Waqar AN; Faham M; Zehnder JL; Miklos DB
Leukemia; 2013 Aug; 27(8):1659-65. PubMed ID: 23419792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]